Insta
Bharat Biotech Gets DCGI Panel's Approval For Phase 3 Trials Of Intranasal COVID-19 Vaccine As Booster Shot: Report
Swarajya Staff
Jan 05, 2022, 05:29 PM | Updated 05:29 PM IST
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
Bharat Biotech has obtained the approval from the Drugs Comptroller General of India (DCGI) for carrying out last-stage trials of its nasal Covid-19 vaccine as a form of booster shots, reports Moneycontrol.
The company had filed its last-stage trial application to the DCGI back in December as it maintained that there would be greater convenience in administering an intranasal vaccine during the mass vaccination campaign.
The drug regulator’s subject expert committee (SEC) has reportedly given an in-principle to Bharat Biotech for conducting the intranasal vaccine’s ‘Phase III superiority study and Phase III booster dose study’ in parallel in wake of the Covid situation in the country.
The development comes as the government had recently announced that Healthcare and frontline workers along with the elderly citizens will receive a ‘precautionary dose’ or a booster shot of the Covid-19 vaccine from 10th January onwards.
So far, Covishield manufactured by the Serum Institute of India (SII) along with Bharat Biotech’s Covaxin have largely dominated the massive vaccination drive carried out in India.
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
Introducing ElectionsHQ + 50 Ground Reports Project
The 2024 elections might seem easy to guess, but there are some important questions that shouldn't be missed.
Do freebies still sway voters? Do people prioritise infrastructure when voting? How will Punjab vote?
The answers to these questions provide great insights into where we, as a country, are headed in the years to come.
Swarajya is starting a project with an aim to do 50 solid ground stories and a smart commentary service on WhatsApp, a one-of-a-kind. We'd love your support during this election season.
Click below to contribute.